Search Results - "Shulman, Matisyahu"

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)" by Shulman, Matisyahu, Weiss, Roger, Rotrosen, John, Novo, Patricia, Costello, Elizabeth, Nunes, Edward V

“…Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications-methadone, buprenorphine, and extended-release…”
Get full text

Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study by Karnik, Niranjan S, Campbell, Cynthia I, Curtis, Megan E, Fiellin, David A, Ghitza, Udi, Hefner, Kathryn, Hser, Yih-Ing, McHugh, R Kathryn, Murphy, Sean M, McPherson, Sterling M, Moran, Landhing, Mooney, Larissa J, Wu, Li-Tzy, Shmueli-Blumberg, Dikla, Shulman, Matisyahu, Schwartz, Robert P, Stephens, Kari A, Watkins, Katherine E, Marsden, John

“…A lack of consensus on the optimal outcome measures to assess the efficacy and effectiveness of interventions for the treatment of opioid use disorder (OUD)…”
Get full text

Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder by Hefner, Kathryn, Choo, Tse-Hwei, Shmueli-Blumberg, Dikla, Pavlicova, Martina, King, Jacquie, Fishman, Marc, Shulman, Matisyahu, Campbell, Aimee, Greiner, Miranda, Scodes, Jennifer, Meyers-Ohki, Sarah, Novo, Patricia, Nunes, Edward, Rotrosen, John

“…•Counseling and 12-Step attendance were associated with later reduced opioid use.•Associations between psychosocial support and use grew over weeks of the…”
Get full text

Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder by Shulman, Matisyahu, Greiner, Miranda, Bisaga, Adam

Get full text

Buprenorphine Treatment for Opioid Use Disorder: An Overview by Shulman, Matisyahu, Wai, Jonathan M., Nunes, Edward V.

“…Opioid use disorder affects over 26 million individuals worldwide. There are currently three World Health Organization-recommended and US Food and Drug…”
Get full text

Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine by Manu, Peter, Rogozea, Liliana M., Shulman, Matisyahu

Get full text

Commentary on Stein et al. (2020): Whither detoxification in the face of the opioid epidemic? by Nunes, Edward V., Shulman, Matisyahu

Get full text

Home-Based Outpatient Telepsychiatry to Improve Adherence With Treatment Appointments: A Pilot Study by Shulman, Matisyahu, John, Majnu, Kane, John M

“…Objective:This study examined whether patients who had been nonadherent with outpatient appointments and who were randomly assigned to receive treatment…”
Get full text

Association of Baseline Fentanyl Use and Opioid Withdrawal Symptoms During Inpatient Buprenorphine Initiation in a Large Multisite Detoxification Trial by Shulman, Matisyahu, Greiner, Miranda, Hu, Mei-Chen, Opara, Onumara, Potter, Kenzie, Ohrtman, Kaitlyn, Nunes, Edward, Bisaga, Adam

Get full text

W83 - Ethical and Methodological Challenges in Studying Discontinuation of Medications for Opioid Use Disorder by Weiss, Roger, Nunes, Edward, Novo, Patricia, Shulman, Matisyahu, Bailey, Genie, Provost, Scott, Meyers-Ohki, Sarah, Liu, David, Rotrosen, John

Get full text

T8 - Association of Baseline Fentanyl Use and Opioid Withdrawal Symptoms During Inpatient Buprenorphine Initiation in a Large Multisite Detoxification Trial by Shulman, Matisyahu, Greiner, Miranda, Hu, Mei-Chen, Opara, Onumara, Potter, Kenzie, Ohrtman, Kaitlyn, Nunes, Edward, Bisaga, Adam

Get full text

Patient Characteristics Associated With Retention on XR-NTX in the CTN-0051 Trial by Opara, Onumara, Ohrtman, Kaitlyn, Greiner, Miranda, Shulman, Matisyahu, Choo, Tse-Hwei, Pavlicova, Martina, Campbell, Aimee, Rotrosen, John, Nunes, Edward

Get full text

Ethical and Methodological Challenges in Studying Discontinuation of Medications for Opioid Use Disorder by Weiss, Roger, Nunes, Edward, Novo, Patricia, Shulman, Matisyahu, Bailey, Genie, Provost, Scott, Meyers-Ohki, Sarah, Liu, David, Rotrosen, John

Get full text

M92 - Patient Characteristics Associated With Retention on XR-NTX in the CTN-0051 Trial by Opara, Onumara, Ohrtman, Kaitlyn, Greiner, Miranda, Shulman, Matisyahu, Choo, Tse-Hwei, Pavlicova, Martina, Campbell, Aimee, Rotrosen, John, Nunes, Edward

Get full text

Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine by Manu, Peter, Rogozea, Liliana M., Shulman, Matisyahu

“…Opioid use disorder continues to have a significant impact on public health morbidity and mortality throughout the United States and elsewhere. Managing opioid…”
Get full text

M118 - Patient Characteristics of Fentanyl Positive Individuals With Opioid Use Disorder by Greiner, Miranda, Hu, Mei-Chen, Shulman, Matisyahu, Hefner, Kathryn, Opara, Onumara, Potter, Kenzie, Ohrtman, Kaitlyn, Ghitza, Udi, Nunes, Edward, Bisaga, Adam

Get full text

Patient Characteristics of Fentanyl Positive Individuals With Opioid Use Disorder by Greiner, Miranda, Hu, Mei-Chen, Shulman, Matisyahu, Hefner, Kathryn, Opara, Onumara, Potter, Kenzie, Ohrtman, Kaitlyn, Ghitza, Udi, Nunes, Edward, Bisaga, Adam

Get full text

Initiating Long-acting Injectable Naltrexone: Procedure for a Second Attempt After a First Attempt Fails by Shulman, Matisyahu, Hu, Mei Chen, Nunes, Edward V., Bisaga, Adam

Get full text

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients by Ross, Rachael K., Nunes, Edward V., Olfson, Mark, Shulman, Matisyahu, Krawczyk, Noa, Stuart, Elizabeth A., Rudolph, Kara E.

“…Background and aims Extended‐release naltrexone (XR‐NTX) and sublingual buprenorphine (SL‐BUP) are both approved for opioid use disorder (OUD) treatment in any…”
Get full text

Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse by Rudolph, Kara E., Shulman, Matisyahu, Fishman, Marc, Díaz, Iván, Rotrosen, John, Nunes, Edward V.

“…Background and Aims Dynamic, adaptive pharmacologic treatment for opioid use disorder (OUD) has been previously recommended over static dosing to prevent…”
Get full text